Skip to main content
SpringerLink
Log in

Natural History of HIV Infection and Evolution of Antiretroviral Therapy

  • Chapter
Cardiovascular Disease in AIDS

Abstract

The are probably few examples, if any, in the story of medicine like the one concerning the abrupt change that pharmacological research determined in the clinical evolution of HIV infection and AIDS. In few months since the introduction of the first triple drug association deserving the acronym HAART (Highly Active Antiretroviral Therapy), the life expectancy of persons infected with HIV switched from a few years to a still indefinable time that we can today estimate as several decades [1]. Those physicians who are sufficiently aged to have assisted HIV-infected patients both before and after the introduction of HAART, have probably experienced one of the most important events in their life. It is often difficult in these times to make young doctors (and young patients as well) aware of the magnitude of the change that took place in the overall life perspective of humans infected with HIV. While for the newcomers to antiretroviral therapy it is rather natural to see patients’ immunity regain its competence under appropriate antiretroviral treatment, some of us still perceive something like a miracle in watching the reversal of such an otherwise deadly human disease. Most of our concerns today are related to side effects resulting from HAART rather than to its efficacy, and we are increasingly focusing on the long-term therapeutic balance (with issues like toxicity, tolerance and adherence) instead of lifethreatening opportunistic infections. A short paragraph on the natural history of HIV infection is thus fully justified in the intention to remind others of how things were, and still are in many geographical regions, before the use of multi-drug therapy transformed HIV infection from a lethal disease to a condition often compatible with a reasonably normal life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Palella FJ, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853–860

    Article  PubMed  Google Scholar 

  2. Gottlieb MS, Schroff R, Schanker HM et al (1981) Pneumocystis carinii pneumonia in homosexual men. N Engl J Med 305:1425–1431

    CAS  PubMed  Google Scholar 

  3. CDC (1982) Kaposi’s sarcoma and Pneumocystis carinii pneumonia in homosexual men: New York City and California. MMWR Morb Mortal Wkly Rep 30:305–330

    Google Scholar 

  4. Goeddert JJ, Biggar RJ, Melbye M et al (1987) Effect of T4 count and cofactors on the incidence of AIDS in homosexual men: an 11-year follow-up. JAMA 257:331–334

    Article  Google Scholar 

  5. Wei X, Ghosh SK, Taylor ME et al (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117–222

    Article  CAS  PubMed  Google Scholar 

  6. Cooper DA, Gold J, Maclean P et al (1985) Acute AIDS retrovirus infection: definition of a clinical illness associated with seroconversion. Lancet 1:537–540

    Article  CAS  PubMed  Google Scholar 

  7. Yanhems P, Routy JP, Hirschel B et al (2002) Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age. J Acquir Immune Defic Syndr 31:318–321

    Google Scholar 

  8. Herard DR, Phillips J, Windsor I et al (1994) Detection of human immunodeficiency virus type 1 p24 antigen and plasma RNA: relevance to indeterminate serologic tests. Transfusion 34:376–380

    Article  Google Scholar 

  9. Bacchetti P, Moss AR (1993) Incubation period of AIDS in San Francisco. Nature 338:251–253

    Article  Google Scholar 

  10. Osmond D, Chaisson RE, Moss A et al (1987) Lymphadenopathy in asymptomatic patients seropositive for HIV. N Engl J Med 317:246

    CAS  PubMed  Google Scholar 

  11. Masur H, Ognibene FP, Yarchoan R et al (1992) CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 111:223–231

    Google Scholar 

  12. Moore RD, Chaisson RD (1996) Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 124:633–642

    CAS  PubMed  Google Scholar 

  13. Janoff EN, Breiman RF, Daley CL et al (1992) Pneumococcal disease during HIV infection. Ann Intern Med 117:314–324

    CAS  PubMed  Google Scholar 

  14. Petruckevich A, Del Amo J, Phillips AN et al (1998) Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London. AIDS 12:107–113

    Google Scholar 

  15. Chaisson RE, Keruly J, Richman DD, Moore DD (1992) Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. Arch Intern Med 152:2009–2013

    Article  CAS  PubMed  Google Scholar 

  16. Tang AM, Forrester J, Spiegelman D et al (2002) Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31:230–236

    PubMed  Google Scholar 

  17. Sepkowitz KA, Telzak EE, Carrow M et al (1993) Fever among outpatients with advanced human immunodeficiency virus infection. Arch Intern Med 153:1909–1912

    Article  CAS  PubMed  Google Scholar 

  18. Serwadda D, Mugerwa RD, Sewankambo NK et al (1985) Slim disease: a new disease in Uganda and its association with HTLVIII infection. Lancet 2(8460):849–852

    Article  CAS  PubMed  Google Scholar 

  19. Theuer CP, Hopewell PC, Elias D et al (1990) Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 162:8–12

    CAS  PubMed  Google Scholar 

  20. Selwyn PA, Hartel D, Lewis VA et al (1989) A prospective study of the risk of tuberculosis among intravenous drug abusers with human immunodeficiency virus infection. N Engl J Med 320:545–550

    CAS  PubMed  Google Scholar 

  21. Di Perri G, Cruciani M, Danzi MC et al (1989) Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 2:1502–1504

    PubMed  Google Scholar 

  22. Jones BE, Young SM, Antoniskis D et al (1993) Relationship of the manifestations of tuberculosis to CD4 cell count in patients with human immunodeficiency virus infection. Am Rev Respir Dis 148:1292–1297

    CAS  PubMed  Google Scholar 

  23. Di Perri G, Cazzadori A, Vento S et al (1996) Comparative histopathology study of pulmonary tuberculosis in HIV-infected and non-infected patients. Tuberc Lung Dis 77:244–249

    Article  Google Scholar 

  24. Corbett EL, Watt CJ, Walker N et al (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163:1009–1021

    Article  PubMed  Google Scholar 

  25. Sheppard HW, Lang W, Ascher MS et al (1993) The characteristics of non-progressors: long-term HIV 1 infection with stable Cd4+ T-cell levels. AIDS 7:1159–1166

    Article  CAS  PubMed  Google Scholar 

  26. Cao Y, Quin L, Zhang L et al (1995) Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 332:201–208

    Article  CAS  PubMed  Google Scholar 

  27. Gallant JE, Moore RD, Chaisson RE (1994) Prophylaxis for opportunistic infection in patients with HIV infection. Ann Intern Med 120:932–943

    CAS  PubMed  Google Scholar 

  28. Graham NM, Zeger SL, Park LP et al (1991) Effects of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. Lancet 338:265–269

    Article  CAS  PubMed  Google Scholar 

  29. Hogg RS, O’haughnessy MV, Gataric N et al (1997) Decline in deaths from AIDS due to new antiretrovirals. Lancet 349:1294

    Article  CAS  PubMed  Google Scholar 

  30. Mocroft A, Vella S, Benfield TL et al (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352:1725–1730

    CAS  Google Scholar 

  31. Browne AE, Malone JD, Zhou SYJ et al (1997) Human immunodeficiency virus RNA levels in US adults: a comparison base on race and ethnicity. J Infect Dis 176:794–797

    Article  Google Scholar 

  32. Yerly S, Perneger TV, Hirshel B et al (1998) A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients: The Swiss HIV cohort study. Arch Intern Med 158:247–252

    Article  CAS  PubMed  Google Scholar 

  33. Sterling TR, Hoover Dr, Astemborsky J et al (2002) Heat-denaturated human immunodeficiency virus type 1 protein p24 antigen: prognostic value in adults with early-stage disease. J Infect Dis 186:1181–1185

    Article  CAS  PubMed  Google Scholar 

  34. Wu H, Kuritzkes DR, McClerman Dr et al (1999) Characterization of viral dynamics in HIV type 1-infected patients treated with combination antiretroviral therapy: relationship to host factors, cellular restoration, and virologic end points. J Infect Dis 179:799–807

    Article  CAS  PubMed  Google Scholar 

  35. Balaram P (2003) The science and politics of AIDS. Curr Sci 85:117–118

    Google Scholar 

  36. Markovitz M, Morales-Ramirez JO, Nguyen BY et al (2006) Antiretroviral activity, pharmacokinetics and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1-infected individuals. J Acquir Immune Defic Syndr 43:509–515

    Article  Google Scholar 

  37. Suligoi B, Boros L, Camoni L et al (2005) Aggiornamento dei casi di AIDS notificati in Italia e delle nuove diagnosi di infezione da HIV. Commissione Nazionale per la Lotta contro l’AIDS. Ministero della Salute, Rome

    Google Scholar 

  38. Powderly WG, Landay A, Lederman MM (1998) Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 280:72–77

    Article  CAS  PubMed  Google Scholar 

  39. Di Perri G, Bonora S, Vento S et al (1998) Highly active antiretroviral therapy. Lancet 351:1056–9

    PubMed  Google Scholar 

  40. Pakker NG, Kroon ED, Roos MT et al (1999) Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS 13:203–212

    Article  CAS  PubMed  Google Scholar 

  41. Di Perri G, Vento S, Mazzi R et al (1999) Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy. J Infect 39:193–197

    Article  PubMed  Google Scholar 

  42. Schneider M, Borleffs JC, Stolk RP et al (1999) Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy. Lancet 353:201–3

    Article  CAS  PubMed  Google Scholar 

  43. Valdez H, Chowdhry TK, Assad R et al (2001) Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995–1999: Clin Infect Dis 32:1487–1493

    Article  CAS  PubMed  Google Scholar 

  44. Department of Health and Human Services (2006) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 10 Oct 2006. http://AIDSinfo.nih.gov

    Google Scholar 

  45. The British HIV Association (2005) BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 6(S2):1–61

    Article  Google Scholar 

  46. Dusheiko G, Antonakopoulos N. (2007) Treatment of hepatitis B. Gut. http://gut.bmj.com/cgi/ content/abstract/gut.2005.077891v1

    Google Scholar 

  47. Hirsh MS, Brun-Vezinet F, Clotet B et al (2003) Antiretroviral drug resistance testing in adults infected with HIV type 1: 2003 recommendations of an international AIDS Society-USA panel. Clin Infect Dis 37:113–128

    Article  Google Scholar 

  48. Kempf DJ, Marsh KC, Kumar G et al (1997) Pharmacokinetic enhancement of inhibitors of the HIV protease by coadministration with ritonavir. Antimicrob Ag Chemother 41:654–660

    CAS  Google Scholar 

  49. Walmsley S, Bernstein B, King M et al (2002) Lopinavir/ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346:2039–2046

    Article  CAS  PubMed  Google Scholar 

  50. Di Giambenedetto S, Brocciale L, Colatigli M et al (2007) Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Antivir Ther 12:835–839

    PubMed  Google Scholar 

  51. Canetti G, Grosset J (1961) Teneur des souches sauvages de Mycobacterium tuberculosis en variants resistants a l’isoniazide et en variants resistants a la streptomycine sur milieu de Lowenstein-Jensen. Ann Inst Pasteur 101:28–42

    CAS  Google Scholar 

  52. Lazzarin A, Clotet B, Cooper D et al (2003) Efficacy of enfuvirtide in patients infected with drugresistant HIV-1 in Europe and Australia. N Engl J Med 348:2186–2195

    Article  CAS  PubMed  Google Scholar 

  53. Carr A, Cooper DA (2001) Adverse effects of antiretroviral therapy. Lancet 356:1423–1430

    Article  Google Scholar 

  54. Calmy A, Hirschel B, Cooper DA, Carr A (2007) Clinical update: adverse effects of antiretroviral therapy. Lancet 370:12–14

    Article  PubMed  Google Scholar 

  55. DAD Study Group (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356:1723–1735

    Article  Google Scholar 

  56. SMART Study Group (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355:2283–2296

    Article  Google Scholar 

  57. Haubrich R, Riddler S, DiRienzo G et al (2007) Metabolic outcome of ACTG 5142; a prospective randomized phase III trial of NRTI-, PIand NNRTI-sparing regimens for initial treatment of HIV 1 infection. Abstr. 38,14th CROI, 25-28 Feb 2007, Los Angeles, CA

    Google Scholar 

  58. Edmunds-Ogbuokiri J (2007) Update: antiretroviral agents in expanded access. HIV Clin 19:4–5

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy

    G. Di Perri, S. Audagnotto, F. Gobbi, L. Trentini, A. Calcagno & S. Bonora

Authors
  1. G. Di Perri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Audagnotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Gobbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Trentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Calcagno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Bonora
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Pathophysiology, “Sapienza” University of Rome, Rome, Italy

    Giuseppe Barbaro

  2. Department of Cardiology Saint Antoine University Hospital, Assistance Publique - Hôpitaux de Paris and Université Pierre et Marie Curie Paris, France

    Franck Boccara

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Italia

About this chapter

Cite this chapter

Di Perri, G., Audagnotto, S., Gobbi, F., Trentini, L., Calcagno, A., Bonora, S. (2009). Natural History of HIV Infection and Evolution of Antiretroviral Therapy. In: Barbaro, G., Boccara, F. (eds) Cardiovascular Disease in AIDS. Springer, Milano. https://doi.org/10.1007/978-88-470-0761-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-0761-1_1

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0760-4

  • Online ISBN: 978-88-470-0761-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation